Find Reports

Select Report Type

Reimbursement Review

Displaying 601 - 625 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Grastofil	Filgrastim	cdr_SE0446_Grastofil.pdf SE0446_cdr_complete_Grastofil_March-22-16_e.pdf SE0446_Grastofil_SEB_Report.pdf SE0446_Grastofil_PI_Submissions.pdf	Neutropenia	List with clinical criteria and/or conditions	Complete	Sep 11, 2015	Mar 18, 2016	SE0446-000
Ferriprox	Deferiprone	cdr_SR0448_Ferriprox.pdf SR0448_cdr_complete_Ferriprox_March-23-16_e.pdf SR0448_Ferriprox_CL_Report.pdf SR0448_Ferriprox_PE_Report.pdf SR0448_Ferriprox_PI_Submissions.pdf	Transfusional iron overload	List with clinical criteria and/or conditions	Complete	Sep 24, 2015	Mar 18, 2016	SR0448-000
Genvoya	Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide	cdr_SR0449_ECFTAF.pdf SR0449_Genvoya_CL_Report-e.pdf SR0449_Genvoya_PE_Report-e.pdf SR0449_complete_Genvoya-March_22-16_e.pdf SR0449 Genvoya_PI_Submissions.pdf	HIV infection	List	Complete	Sep 24, 2015	Mar 18, 2016	SR0449-000
Jakavi	Ruxolitinib	pcodr_profund_ruxolitinib_jakavi_pv.pdf pcodr_ruxolitinib_jakavi_pv_fn_rec.pdf pcodr_ruxolitinib_jakavi_pv_fn_cgr.pdf pcodr_ruxolitinib_jakavi_pv_fn_egr.pdf pcodr_ruxolitinib_jakavi_pv_in_rec.pdf pcodr_ruxolitinib_jakavi_pv_pagfdk.pdf pcodr_ruxolitinib_jakavi_pv_fdk_novartis.pdf pcodr_ruxolitinib_jakavi_pv_ptfdk_mpn.pdf pcodr_ruxolitinib_jakavi_pv_coi_mpn.pdf	Polycythemia vera	Reimburse with clinical criteria and/or conditions	Complete	Aug 27, 2015	Mar 3, 2016	PC0065-000
Xgeva	Denosumab (Drug Plan Submission)	SR0433-000 Xgeva.pdf SR0433-000_complete_Xgeva_BC-Mar_1_16_e.pdf SR0433_000_XgevaBC_CL_Report.pdf SR0433_000_XgevaBC_PE_Report.pdf	Prevention of skeletal-related events due to bone metastases from breast cancer	List with clinical criteria and/or conditions	Complete	Jul 31, 2015	Feb 25, 2016	SR0433-000
Jinarc	Tolvaptan	SR0435 Jinarc.pdf SR0435_complete_Jinarc-Feb_26_16_e.pdf SR0435_Jinarc_CL_Report.pdf SR0435_Jinarc_PE_Report.pdf SR0435 Jinarc Template_PI_Submissions.pdf	Autosomal dominant polycystic kidney disease	Do not list	Complete	May 29, 2015	Feb 24, 2016	SR0435-000
Naglazyme	Galsulfase (Drug Plan Submission)	cdr_SR0434_Naglazyme.pdf SR0434_complete_Naglazyme-Feb-23_16_e.pdf SR0434_Naglazyme_CL_Report.pdf SR0434_Naglazyme_PE_Report.pdf SR0434_Naglazyme_PI_Submissions.pdf	Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)	List with clinical criteria and/or conditions	Complete	Aug 20, 2015	Feb 19, 2016	SR0434-000
Repatha	Evolocumab	cdr_SR0441_Repatha.pdf SR0441_complete_Rapatha-Feb-23_16_e.pdf SR0441_Repatha_CL_Report.pdf SR0441_Repatha_PE_Report.pdf SR0441_Repatha_PI_Submissions.pdf	Primary hyperlipidemia; mixed dyslipidemia	List with clinical criteria and/or conditions	Complete	Jun 30, 2015	Feb 19, 2016	SR0441-000
Breo Ellipta	Fluticasone Furoate and Vilanterol (as trifenatate)	cdr_SR0442_Breo-Ellipta.pdf SR0442_complete_Breo Ellipta-Feb-22-16_e.pdf SR0442_BreoEllipta_CL_Report.pdf SR0442_BreoEllipta_PE_Report.pdf SR0442_BreoEllipta_PI_Submissions.pdf	Asthma	List with clinical criteria and/or conditions	Complete	Aug 10, 2015	Feb 18, 2016	SR0442-000
Otezla	Apremilast	cdr_SR0437_Otezla_PsA.pdf SR0437_complete_Otezla_PsA-Dec-21-15_e.pdf SR0437_OtezlaPsA_CL_Report.pdf SR0437_OtezlaPsA_PE_Report.pdf SR0437_OtezlaPsA_PI_Submissions.pdf	Arthritis, psoriatic	List with criteria/condition	Complete	Jun 8, 2015	Dec 17, 2015	SR0437-000
Arnuity Ellipta	Fluticasone furoate	cdr_SR0439_fluticasone_furoate.pdf SR0439_complete_Arnuity-Ellipta-Dec-21-15_e.pdf SR0439_Arnuity_Ellipta_CL_Report.pdf SR0439_Arnuity_Ellipta_PE_Report.pdf SR0439_Arnuity_Ellipta_PI_Submissions.pdf	Asthma	List with criteria/condition	Complete	Jun 26, 2015	Dec 17, 2015	SR0439-000
Inspiolto Respimat	Tiotropium / olodaterol	cdr_SR0436_Inspiolto_Respimat.pdf SR0436_complete_Inspiolto-Respimat-Dec_21-15-e.pdf SR0436_Inspiolto_Respimat_CL_Report.pdf SR0436_Inspiolto_Respimat_PE_Report.pdf SR0436_Inspiolto_Respimat_PI_Submissions.pdf	Chronic obstructive pulmonary disease	List with criteria/condition	Complete	Jun 4, 2015	Dec 17, 2015	SR0436-000
Adempas	Riociguat	cdr_SR0438_Adempas-PAH.pdf SR0438_complete_Adempas-Dec-21-15_e.pdf SR0438_Adempas_CL_Report.pdf SR0438_Adempas_PE_Report.pdf SR0438_Adempas_PI_Submissions.pdf	Pulmonary arterial hypertension (WHO group 1)	List with clinical criteria and/or conditions	Complete	Jun 25, 2015	Dec 17, 2015	SR0438-000
Plegridy	Peginterferon beta-1a	SR0440 Plegridy.pdf SR0440_complete_Plegridy-Dec-21-15_e.pdf SR0440_Plegridy_CL_Report.pdf SR0440_Plegridy_PE_Report.pdf SR0440_Plegridy Patient Input Submission.pdf	Multiple sclerosis, relapsing-remitting	List with criteria/condition	Complete	Jun 26, 2015	Dec 17, 2015	SR0440-000
Vectibix	Panitumumab	pcodr_provfund_panitumumab_vectibix_mcrc.pdf pcodr_panitumumab_vectibix_mcrc_fn_rec.pdf pcodr_panitumumab_vectibix_mcrc_fn_cgr.pdf pcodr_panitumumab_vectibix_mcrc_fn_egr.pdf pcodr_panitumumab_vectibix_mcrc_in_rec.pdf pcodr_panitumumab_vectibix_mcrc_pagfdk.pdf pcodr_panitumumab_vectibix_mcrc_fdk_amgen.pdf pcodr_panitumumab_vectibix_mcrc_coi_ccac.pdf	Metastatic Colorectal Cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 15, 2015	Dec 3, 2015	PC0060-000
Revlimid	Lenalidomide	pcodr_provfund_lenalidomide_revlimid_nd-mm.pdf pcodr_lenalidomide_revlimid_nd-mm_fn_rec.pdf pcodr_lenalidomide_revlimid_nd-mm_fn_cgr.pdf pcodr_lenalidomide_revlimid_nd-mm_fn_egr.pdf pcodr_lenalidomide_revlimid_mm_in_rec.pdf pcodr_lenalidomide_revlimid_nd-mm_pagfdk.pdf pcodr_lenalidomide_revlimid_nd-mm_fdk_celgene.pdf pcodr_lenalidomide_revlimid_nd-mm_coi_mc.pdf	Multiple Myeloma, newly diagnosed	Reimburse with clinical criteria and/or conditions	Complete	May 4, 2015	Dec 3, 2015	PC0061-000
Zykadia	Ceritinib	pcodr_provfund_ceritinib_zykadia_nsclc.pdf pcodr_ceritinib_zykadia_nsclc_fn_rec.pdf pcodr_ceritinib_zykadia_nsclc_fn_cgr.pdf pcodr_ceritinib_zykadia_nsclc_fn_egr.pdf pcodr_ceritinib_zykadia_nsclc_in_rec.pdf pcodr_ceritinib_zykadia_nsclc_pagfdk.pdf pcodr_ceritinib_zykadia_nsclc_fdk_novartis.pdf pcodr_ceritinib_zykadia_nsclc_ptfdk_lcc.pdf pcodr_ceritinib_zykadia_nsclc_coi_lcc.pdf	Metastatic Non-Small Cell Lung Cancer	Do not reimburse	Complete	Jun 5, 2015	Dec 3, 2015	PC0062-000
Forxiga	Dapagliflozin	Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Diabetes mellitus, type 2	List with clinical criteria and/or conditions	Complete	Apr 30, 2015	Nov 20, 2015	SR0428-000
Rosiver	Ivermectin	SR0429 Rosiver.pdf SR0429_complete_Rosiver_Nov-23-15_e.pdf SR0429_Rosiver_CL_Report.pdf SR0429_Rosiver_PE_Report.pdf SR0429 Rosiver_PI_Submissions_Consolidated_validated.pdf	Rosacea	List with criteria/condition	Complete	Apr 30, 2015	Nov 19, 2015	SR0429-000
Kalydeco	Ivacaftor	cdr_SR0430_Kalydeco_R117H.pdf SR0430_complete_Kalydeco_R117H_Nov-23-15_e.pdf SR0430_KalydecoR117H_CL_Report.pdf SR0430_KalydecoR117H_PE_Report.pdf SR0430_KalydecoR117H_PI_Submissions.pdf	Cystic fibrosis, R117H CFTR gating mutation	List with criteria/condition	Complete	May 8, 2015	Nov 19, 2015	SR0430-000
Neupro	Rotigotine	cdr_SR0432_Neupro_Resubmission.pdf SR0432_complete_Neupro_Resb_Nov-24-15_e.pdf SR0432_Neupro_CL_Report_resub.pdf SR0432_Neupro_PE_Report_resub.pdf SR0432_Neupro_PI_Submissions.pdf	Parkinson’s disease	List with clinical criteria and/or conditions	Complete	May 21, 2015	Nov 19, 2015	SR0432-000
Keytruda	Pembrolizumab	pcodr_provfund_pembrolizumab_keytruda_mm.pdf pcodr_pembrolizumab_keytruda_mm_fn_rec.pdf pcodr_pembrolizumab_keytruda_mm_fn_cgr.pdf pcodr_pembrolizumab_keytruda_mm_fn_egr.pdf pcodr_pembrolizumab_keytruda_mm_in_rec.pdf pcodr_pembrolizumab_keytruda_mm_pagfdk.pdf pcodr_pembrolizumab_keytruda_mm_fdk-merck.pdf pcodr_pembrolizumab_keytruda_mm_ptfdk_sysf.pdf pcodr_pembrolizumab_keytruda_mm_ptfdk_mnc.pdf pcodr_pembrolizumab_keytruda_mm_coi_sysf.pdf pcodr_pembrolizumab_keytruda_mm_coi_mnc.pdf pcodr_pembrolizumab_keytruda_mm_coi_cspa.pdf	Metastatic Melanoma	Reimburse with clinical criteria and/or conditions	Complete	Apr 16, 2015	Nov 16, 2015	PC0058-000
Cyramza	Ramucirumab	pcodr_profund_ramucirumab_cyramza_gc.pdf pcodr_ramucirumab_cyramza_gc_fn_rec.pdf pcodr_ramucirumab_cyramza_gc_fn_cgr.pdf pcodr_ramucirumab_cyramza_gc_fn_egr.pdf pcodr_ramucirumab_cyramza_gc_in_rec.pdf pcodr_ramucirumab_cyramza_gc-pagfdk.pdf pcodr_ramucirumab_cyramza_gc-fdk-elc.pdf	Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma	Reimburse with clinical criteria and/or conditions	Complete	Apr 15, 2015	Oct 29, 2015	PC0059-000
Elelyso	Taliglucerase alfa	cdr_SR0390_Elelyso.pdf SR0390_Elelyso_Oct-30-15.pdf SR0390_Elelyso_CL_Report.pdf SR0390_Elelyso_PE_Report.pdf	Gaucher disease	Do not list	Complete	Aug 15, 2014	Oct 28, 2015	SR0390-000
Cosentyx	Secukinumab	TS0001-PsO-Updated-Streamlined-Rec.pdf cdr_SR0407_Cosentyx.pdf SR0407_Cosentyx_Oct-30-15.pdf SR0407_Cosentyx_CL_Report.pdf SR0407_Cosentyx_PE_Report.pdf SR0407_Cosentyx_PI_Submissions.pdf	Plaque psoriasis	List with criteria/condition	Complete	Dec 8, 2014	Oct 28, 2015	SR0407-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 601 - 625 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Reducing the Environmental Impact of Clinical Care	Reducing the Environmental Impact of Clinical Care	Apr 20, 2023	Horizon Scan		Completed	EH0112-000
CADTH Pharmaceutical Reviews Update — Issue 36		Apr 20, 2023	Reimbursement Review	Pharmaceutical Review Update
brolucizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 19, 2023	Reimbursement Review		Complete	SR0747-000
lemborexant	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 19, 2023	Reimbursement Review		Complete	SR0716-000
dupilumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 18, 2023	Reimbursement Review		Complete	SR0745-000
lurbinectedin	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 18, 2023	Reimbursement Review		Complete	PC0281-000
dupilumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 13, 2023	Reimbursement Review		Complete	SF0754-000
Laser Treatment for Lower Back Pain	Laser Treatment for Lower Back Pain	Apr 12, 2023	Horizon Scan	Health Technology Update	Completed	EN0044-000
Large B-Cell Lymphoma	Final Report	Apr 11, 2023	Reimbursement Review	Provisional Funding Algorithm	Completed	PH0027-000
belimumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 10, 2023	Reimbursement Review		Complete	SR0746-000
CADTH Pharmaceutical Reviews Update — Issue 35		Mar 30, 2023	Reimbursement Review	Pharmaceutical Review Update
darolutamide	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Mar 28, 2023	Reimbursement Review		Complete	PC0294-000
Formulary Management of Biologics in Plaque Psoriasis	Formulary Management of Biologics in Plaque Psoriasis	Mar 24, 2023	Health Technology Review	Technology Review	Completed	HD0011-000
Living With Type 2 Diabetes	Living With Type 2 Diabetes	Mar 24, 2023	Health Technology Review	Technology Review	Completed	HC0045-000
Tocilizumab for Neuromyelitis Optica Spectrum Disorder	Tocilizumab for Neuromyelitis Optica Spectrum Disorder	Mar 24, 2023	Health Technology Review	Rapid Review	Completed	RC1477-000
Canakinumab for Adult-Onset Still Disease	Canakinumab for Adult-Onset Still Disease	Mar 22, 2023	Health Technology Review	Rapid Review	Completed	RC1475-000
ferumoxytol		Mar 20, 2023	Reimbursement Review		Withdrawn	SR0753-000
pembrolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Mar 20, 2023	Reimbursement Review		Complete	PC0295-000
Formulary Management of Targeted Immune Modulators for Ulcerative Colitis: Environmental Scan	Formulary Management of Targeted Immune Modulators in Ulcerative Colitis	Mar 16, 2023	Health Technology Review	Environmental Scan	Completed	ES0366-000
eptinezumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Mar 15, 2023	Reimbursement Review		Complete	SR0743-000
pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Mar 15, 2023	Reimbursement Review		Complete	PC0292-000
Longevity of Partial and Complete Dentures	Longevity of Partial and Complete Dentures	Mar 14, 2023	Health Technology Review	Rapid Review	Completed	RC1474-000
pegvaliase	Memorandum report to CADTH Response to the Procedural Review Panel’s Memorandum Report on the Procedural R…Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Mar 13, 2023	Reimbursement Review		Complete	SR0712-000
Dental Bridges for Partial Tooth Loss	Dental Bridges for Partial Tooth Loss	Mar 13, 2023	Health Technology Review	Peer-reviewed Summary with Critical Appraisal	Completed	RD0068-000
Policies for Pediatric Medicines		Mar 10, 2023	Health Technology Review	Environmental Scan	In Progress	ES0376-000